{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:03:35Z","timestamp":1740171815180,"version":"3.37.3"},"reference-count":52,"publisher":"Wiley","license":[{"start":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T00:00:00Z","timestamp":1712880000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100015690","name":"Universitas Padjadjaran","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015690","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Disease Markers"],"published-print":{"date-parts":[[2024,4,12]]},"abstract":"<jats:p>Background. Chronic myeloid leukemia (CML) or chronic granulocytic leukemia is a myeloproliferative neoplasm indicated by the presence of the Philadelphia (Ph+) chromosome. First-line tyrosine kinase inhibitor, imatinib, is the gold standard for treatment. However, there has been known unresponsiveness to treatment, especially due to the involvement of other genes, such as the Janus kinase 2 (JAK2) gene. This study aimed to evaluate the relationships between JAK2 levels and complete hematological response (CHR), as well as early molecular response (EMR) after 3 months of imatinib treatment in patients with chronic phase CML. Methods. Patients with Ph+\u2009CML in the chronic phase (n\u2009=\u200940; mean age, 40\u2009\u00b1\u200911 years) were recruited to complete assessments consisting of clinical examination and blood test, including evaluation of complete blood counts and the JAK2 levels, at baseline and following 3 months of therapy with imatinib (at an oral dose of 400\u2009mg per day). Subjects were divided into two groups according to the presence of CHR and EMR. Results. JAK2 gene levels, phosphorylated, and total JAK2 proteins at baseline were significantly lower in the group with the presence of CHR and EMR. In addition, baseline JAK2 levels, including JAK2 gene expression, phosphorylated, and total JAK2 proteins, were negatively correlated with the presence of CHR and EMR. Conclusions. Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.<\/jats:p>","DOI":"10.1155\/2024\/2906566","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T21:50:08Z","timestamp":1712958608000},"page":"1-9","source":"Crossref","is-referenced-by-count":0,"title":["JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib"],"prefix":"10.1155","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9446-2307","authenticated-orcid":true,"given":"Indra","family":"Wijaya","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad H.","family":"Bashari","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lelani","family":"Reniarti","sequence":"additional","affiliation":[{"name":"Department of Child Health, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9346-2041","authenticated-orcid":true,"given":"Anita","family":"Rahmawati","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rully M. A.","family":"Roesli","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Hypertension, Department of Internal Medicine, Faculty of Medicine, Hasan Sadikin General Hospital, Universitas Padjadjaran, Bandung, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","reference":[{"doi-asserted-by":"publisher","key":"1","DOI":"10.1093\/annonc\/mds228"},{"doi-asserted-by":"publisher","key":"2","DOI":"10.1590\/s1679-45082011rb2022"},{"doi-asserted-by":"publisher","key":"3","DOI":"10.1002\/ajh.25011"},{"doi-asserted-by":"publisher","key":"4","DOI":"10.1182\/blood.V96.10.3343"},{"doi-asserted-by":"publisher","key":"5","DOI":"10.4161\/23723548.2014.963450"},{"doi-asserted-by":"publisher","key":"6","DOI":"10.1038\/sj.leu.2402577"},{"doi-asserted-by":"publisher","key":"7","DOI":"10.1182\/blood-2013-05-501569"},{"doi-asserted-by":"publisher","key":"8","DOI":"10.6004\/jnccn.2018.0071"},{"doi-asserted-by":"publisher","key":"9","DOI":"10.1172\/JCI35721"},{"doi-asserted-by":"publisher","key":"10","DOI":"10.1002\/ajh.23691"},{"doi-asserted-by":"publisher","key":"11","DOI":"10.1056\/NEJMoa1609324"},{"doi-asserted-by":"publisher","key":"12","DOI":"10.1016\/j.leukres.2010.04.016"},{"doi-asserted-by":"publisher","key":"13","DOI":"10.1016\/j.hoc.2011.09.004"},{"doi-asserted-by":"publisher","key":"14","DOI":"10.5581\/1516-8484.20110124"},{"key":"15","article-title":"The role of Jak2 inhibitors in the management of CML: can we rest the case ?","volume":"1","author":"P. Gallipoli","year":"2014","journal-title":"Science Proceedings"},{"issue":"2","key":"16","first-page":"1611","article-title":"JAK-STAT pathway genes in predicting the imatinib resistance of CML patients","volume":"48","author":"M. Gorre","year":"2014","journal-title":"International Journal of Cancer Research"},{"issue":"1","key":"17","first-page":"3439","article-title":"JAK2 V617F mutation: a marker for CML progression ?","volume":"13","author":"M. Gorre","year":"2013","journal-title":"Journal of Cell and Tissue Research"},{"doi-asserted-by":"publisher","key":"18","DOI":"10.1074\/jbc.R700016200"},{"doi-asserted-by":"publisher","key":"19","DOI":"10.1182\/blood-2015-01-621110"},{"doi-asserted-by":"publisher","key":"20","DOI":"10.1182\/blood-2013-02-485573"},{"issue":"1","key":"21","article-title":"Evolution of the JAK-STAT pathway","volume":"2","author":"C. Liongue","year":"2014","journal-title":"JAKSTAT"},{"doi-asserted-by":"publisher","key":"22","DOI":"10.1186\/2050-7771-1-5"},{"doi-asserted-by":"publisher","key":"23","DOI":"10.1093\/jmcb\/mjp054"},{"doi-asserted-by":"publisher","key":"24","DOI":"10.3324\/haematol.2015.132142"},{"doi-asserted-by":"publisher","key":"25","DOI":"10.1182\/blood-2011-11-395228"},{"doi-asserted-by":"publisher","key":"26","DOI":"10.1038\/sj.onc.1204834"},{"doi-asserted-by":"publisher","key":"27","DOI":"10.1038\/sj.onc.1205942"},{"issue":"9","key":"28","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1182\/blood-2013-12-545640","article-title":"JAK2\/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo","volume":"124","author":"P. Gallipoli","year":"2014","journal-title":"Blood"},{"issue":"20","key":"29","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"D. A. Arber","year":"2016","journal-title":"Blood"},{"issue":"4","key":"30","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"J. E. Sokal","year":"1984","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"31","DOI":"10.1182\/blood-2010-12-319038"},{"doi-asserted-by":"publisher","key":"32","DOI":"10.1093\/jnci\/90.11.850"},{"doi-asserted-by":"publisher","key":"33","DOI":"10.1200\/JCO.2011.38.6565"},{"doi-asserted-by":"publisher","key":"34","DOI":"10.1182\/blood-2013-06-511592"},{"doi-asserted-by":"publisher","key":"35","DOI":"10.1182\/blood-2012-11-466037"},{"doi-asserted-by":"publisher","key":"36","DOI":"10.1007\/s11899-017-0375-0"},{"doi-asserted-by":"publisher","key":"37","DOI":"10.1038\/s41375-020-0776-2"},{"doi-asserted-by":"publisher","key":"38","DOI":"10.1182\/blood-2009-03-209262"},{"doi-asserted-by":"publisher","key":"39","DOI":"10.1002\/ajh.23887"},{"doi-asserted-by":"publisher","key":"40","DOI":"10.1038\/leu.2009.38"},{"issue":"1","key":"41","first-page":"8","article-title":"Chronic myeloid leukaemia in the 21st century","volume":"76","author":"R. Frazer","year":"2007","journal-title":"The Ulster Medical Journal"},{"doi-asserted-by":"publisher","key":"42","DOI":"10.1200\/JCO.2015.66.2866"},{"doi-asserted-by":"publisher","key":"43","DOI":"10.1002\/cncr.28106"},{"doi-asserted-by":"publisher","key":"44","DOI":"10.4084\/mjhid.2014.007"},{"doi-asserted-by":"publisher","key":"45","DOI":"10.1309\/LMR1KA61JYKUXRDX"},{"key":"46","first-page":"1","article-title":"Variation in adherence measures to imatinib therapy","volume":"4","author":"U. Yamanandra","year":"2017","journal-title":"Journal of Global Oncology"},{"doi-asserted-by":"publisher","key":"47","DOI":"10.4103\/1110-1067.170221"},{"doi-asserted-by":"publisher","key":"48","DOI":"10.21705\/mcbs.v3i2.56"},{"doi-asserted-by":"publisher","key":"49","DOI":"10.4103\/ijmpo.ijmpo_104_16"},{"doi-asserted-by":"publisher","key":"50","DOI":"10.1177\/2040620712468289"},{"issue":"8","key":"51","first-page":"472","article-title":"JAK2V617F mutation in chronic myeloid leukemia predicts early disease progression","volume":"21","author":"Z.-A.-A. Pahore","year":"2011","journal-title":"Journal of the College Physicians Surgeon Pakistan"},{"issue":"1","key":"52","first-page":"1","article-title":"JAK\/STAT as a novel target for the treatment of leukemia","volume":"6","author":"S. Chaudari","year":"2014","journal-title":"International Journal of Pharmacy and Pharmaceutical Sciences"}],"container-title":["Disease Markers"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2024\/2906566.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2024\/2906566.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/dm\/2024\/2906566.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T21:50:20Z","timestamp":1712958620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.hindawi.com\/journals\/dm\/2024\/2906566\/"}},"subtitle":[],"editor":[{"given":"Muhammad","family":"Babar Khawar","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,4,12]]},"references-count":52,"alternative-id":["2906566","2906566"],"URL":"https:\/\/doi.org\/10.1155\/2024\/2906566","relation":{},"ISSN":["1875-8630","0278-0240"],"issn-type":[{"type":"electronic","value":"1875-8630"},{"type":"print","value":"0278-0240"}],"subject":[],"published":{"date-parts":[[2024,4,12]]}}}